首页 > 最新文献

Annales De Dermatologie Et De Venereologie最新文献

英文 中文
Subungual metastasis of melanoma 掌下黑色素瘤转移
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-20 DOI: 10.1016/j.annder.2025.103455
F.K. Pham , G. Chidiac , J. Tantot , L. Thomas
{"title":"Subungual metastasis of melanoma","authors":"F.K. Pham , G. Chidiac , J. Tantot , L. Thomas","doi":"10.1016/j.annder.2025.103455","DOIUrl":"10.1016/j.annder.2025.103455","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103455"},"PeriodicalIF":2.8,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy following home-based intravaginal desensitization to human seminal plasma 家庭阴道内对人精浆脱敏后的妊娠。
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-20 DOI: 10.1016/j.annder.2025.103456
O. Alemany , A. Belbézier , P. Pralong
{"title":"Pregnancy following home-based intravaginal desensitization to human seminal plasma","authors":"O. Alemany , A. Belbézier , P. Pralong","doi":"10.1016/j.annder.2025.103456","DOIUrl":"10.1016/j.annder.2025.103456","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103456"},"PeriodicalIF":2.8,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings 塞鲁美替尼治疗nf1相关丛状神经纤维瘤的第一年在现实生活中具有医学挑战性。
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-17 DOI: 10.1016/j.annder.2025.103438
P. Boitez , D. Farges , M. Descamps , V. Bournazel , L. Martin

Background

Plexiform neurofibromas (PNFs) occur in 20–50 % of NF1 patients and can alter skin appearance and/or invade adjacent structures. These tumors grow rapidly in childhood, leading to significant morbidity. Surgical treatment is recommended as first-line therapy, but complete resection is not always possible, and the risk of recurrence is high. Selumetinib is a selective inhibitor of MEK protein kinases that has been shown to reduce PNF tumor volume. It has been approved as monotherapy for the treatment of symptomatic inoperable PNF in children aged over 3 years. The aim of our study was to investigate the real-life efficacy and safety profile of selumetinib in a single-center cohort of NF1 patients with one or more symptomatic inoperable PNFs.

Patients and methods

Prior to treatment, patients underwent cardiac ultrasound, ophthalmological examination, biological tests, and baseline magnetic resonance imaging (MRI). Specific patient follow-up included a quarterly consultation (with comparative pictures) and a monthly teleconsultation for the first 4 months to discuss any adverse effects, give advice, and provide support to patients and their families. Monitoring included biological, ophthalmological, cardiological and radiological assessment.

Results

From a pediatric NF1 cohort of over one hundred children, we included 10 patients over the age of 18 months (median age 14 years − range 5 to 17 years). Morbidities engendered by PNFs were disfigurement (50 %), pain (30 %), visual impairment (20 %) (mainly amblyopia), hearing impairment (10 %), and balance disorders (10 %). Selumetinib was administered at a dose of 25 mg/m2/day. After a median follow-up period of 19.5 months (±6.6 months), tumor volume shrinkage was observed clinically in 6 cases, stability in 2 cases, and volume growth in 2 cases.
Adverse events were mainly cutaneous (70 %), with acneiform rashes (60 %), xerosis cutis (20 %), alopecia (20 %), paronychia (10 %) and eczematous rash (10 %). Four patients (40 %) presented gastrointestinal disorders at the start of treatment. All these effects corresponded to grade 1 toxicity. No ocular or cardiac toxicity was detected.

Discussion

Our efficacy results at 19.5 months for selumetinib show a genuine but modest reduction in PNF volume. The treatment has a good safety profile. While it is very common for adverse events to be reported at the start of treatment, they are of moderate severity and are managed by dose reduction or simple symptomatic treatment. Starting treatment early in life appears to lead to a more favorable outcome and should be considered.
背景:丛状神经纤维瘤(PNFs)发生在20- 50% %的NF1患者中,可改变皮肤外观和/或侵犯邻近结构。这些肿瘤在儿童时期生长迅速,导致显著的发病率。手术治疗建议作为一线治疗,但完全切除并不总是可能的,而且复发的风险很高。Selumetinib是一种选择性MEK蛋白激酶抑制剂,已被证明可以减少PNF肿瘤体积。它已被批准作为治疗3岁以上 岁儿童症状性不能手术的PNF的单一疗法。本研究的目的是研究selumetinib在伴有一个或多个症状性不能手术的pnf的NF1患者的单中心队列中的实际疗效和安全性。患者和方法:治疗前,患者接受心脏超声、眼科检查、生物学检查和基线磁共振成像(MRI)检查。具体的患者随访包括前4个月( )的季度咨询(带有对比图片)和每月远程咨询,讨论任何不良反应,给出建议,并为患者及其家属提供支持。监测包括生物学、眼科、心脏学和放射学评估。结果:从100多名儿童的小儿NF1队列中,我们纳入了10名年龄在18 个月以上的患者(中位年龄14 岁-范围5至17 岁)。PNFs引起的发病率为毁容(50% %)、疼痛(30% %)、视力损害(20% %)(主要是弱视)、听力损害(10 %)和平衡障碍(10 %)。塞鲁美替尼的剂量为25 mg/m2/天。中位随访19.5 个月(±6.6 个月),临床观察肿瘤体积缩小6例,稳定2例,体积增大2例。不良反应主要为皮肤(70 %),有痤疮样皮疹(60 %)、皮肤干燥(20 %)、脱发(20 %)、甲沟炎(10 %)和湿疹疹(10 %)。4例患者(40 %)在治疗开始时出现胃肠道疾病。所有这些影响都符合1级毒性。未发现眼部或心脏毒性。讨论:我们在19.5 个月时对selumetinib的疗效结果显示PNF体积真正但适度地减少。该疗法具有良好的安全性。虽然在治疗开始时报告不良事件是很常见的,但它们的严重程度为中等,可通过减少剂量或简单对症治疗加以控制。在生命早期开始治疗似乎会导致更有利的结果,应该予以考虑。
{"title":"The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings","authors":"P. Boitez ,&nbsp;D. Farges ,&nbsp;M. Descamps ,&nbsp;V. Bournazel ,&nbsp;L. Martin","doi":"10.1016/j.annder.2025.103438","DOIUrl":"10.1016/j.annder.2025.103438","url":null,"abstract":"<div><h3>Background</h3><div>Plexiform neurofibromas (PNFs) occur in 20–50 % of NF1 patients and can alter skin appearance and/or invade adjacent structures. These tumors grow rapidly in childhood, leading to significant morbidity. Surgical treatment is recommended as first-line therapy, but complete resection is not always possible, and the risk of recurrence is high. Selumetinib is a selective inhibitor of MEK protein kinases that has been shown to reduce PNF tumor volume. It has been approved as monotherapy for the treatment of symptomatic inoperable PNF in children aged over 3 years. The aim of our study was to investigate the real-life efficacy and safety profile of selumetinib in a single-center cohort of NF1 patients with one or more symptomatic inoperable PNFs.</div></div><div><h3>Patients and methods</h3><div>Prior to treatment, patients underwent cardiac ultrasound, ophthalmological examination, biological tests, and baseline magnetic resonance imaging (MRI). Specific patient follow-up included a quarterly consultation (with comparative pictures) and a monthly teleconsultation for the first 4 months to discuss any adverse effects, give advice, and provide support to patients and their families. Monitoring included biological, ophthalmological, cardiological and radiological assessment.</div></div><div><h3>Results</h3><div>From a pediatric NF1 cohort of over one hundred children, we included 10 patients over the age of 18 months (median age 14 years − range 5 to 17 years). Morbidities engendered by PNFs were disfigurement (50 %), pain (30 %), visual impairment (20 %) (mainly amblyopia), hearing impairment (10 %), and balance disorders (10 %). Selumetinib was administered at a dose of 25 mg/m<sup>2</sup>/day. After a median follow-up period of 19.5 months (±6.6 months), tumor volume shrinkage was observed clinically in 6 cases, stability in 2 cases, and volume growth in 2 cases.</div><div>Adverse events were mainly cutaneous (70 %), with acneiform rashes (60 %), xerosis cutis (20 %), alopecia (20 %), paronychia (10 %) and eczematous rash (10 %). Four patients (40 %) presented gastrointestinal disorders at the start of treatment. All these effects corresponded to grade 1 toxicity. No ocular or cardiac toxicity was detected.</div></div><div><h3>Discussion</h3><div>Our efficacy results at 19.5 months for selumetinib show a genuine but modest reduction in PNF volume. The treatment has a good safety profile. While it is very common for adverse events to be reported at the start of treatment, they are of moderate severity and are managed by dose reduction or simple symptomatic treatment. Starting treatment early in life appears to lead to a more favorable outcome and should be considered.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103438"},"PeriodicalIF":2.8,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergological work-up of severe cutaneous adverse reactions with suspicion of anxiolytics or sleeping pills. A multicenter retrospective study of 20 cases 严重皮肤不良反应的过敏检查,怀疑有抗焦虑药或安眠药。20例病例的多中心回顾性研究。
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-01 DOI: 10.1016/j.annder.2025.103398
S. Ingen-Housz-Oro , F. Dezoteux , C. Bernier , E. Le Bidre , D. Staumont-Sallé , A. Welfringer-Morin , V. Beaulieu , M. Tauber , K. Bel Hareth , H. Assier
{"title":"Allergological work-up of severe cutaneous adverse reactions with suspicion of anxiolytics or sleeping pills. A multicenter retrospective study of 20 cases","authors":"S. Ingen-Housz-Oro ,&nbsp;F. Dezoteux ,&nbsp;C. Bernier ,&nbsp;E. Le Bidre ,&nbsp;D. Staumont-Sallé ,&nbsp;A. Welfringer-Morin ,&nbsp;V. Beaulieu ,&nbsp;M. Tauber ,&nbsp;K. Bel Hareth ,&nbsp;H. Assier","doi":"10.1016/j.annder.2025.103398","DOIUrl":"10.1016/j.annder.2025.103398","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103398"},"PeriodicalIF":2.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin ultra-sound: Its history and advances 皮肤超声波:它的历史和进展。
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-01 DOI: 10.1016/j.annder.2025.103437
J. Chauvel-Picard , A.Gleizal , H. Zahouani , L. Tognetti , E. Cinott , E. Lange , M. Suppa , P. Rubegni , V.Del Marmol , C. Raffaelli , P. Bahadoran , J.-L. Perrot
Skin ultrasound imaging has proven its complementarity with in vivo dermatoscopic and microscopic clinical dermatological examination in obtaining additional informations on the deep component of different skin pathologies. It is a reliable and non-invasive tool for evaluating the overall morphology of skin tumors or other pathologies such as Verneuil’s disease or other cystic pathologies.This article resumes the history of skin ultrasound imaging, its technical specificities and its practical uses. Optical imaging is not discussed, for which an article has already been devoted to it.
在获取不同皮肤病理深层成分的额外信息方面,皮肤超声成像已经证明了它与体内皮肤镜和显微临床皮肤学检查的互补性。它是一种可靠的、无创的工具,用于评估皮肤肿瘤或其他病理,如维尔纳伊病或其他囊性病理的整体形态。本文回顾了皮肤超声成像的历史、技术特点和实际应用。光学成像没有讨论,这方面已经有一篇文章专门讨论过。
{"title":"Skin ultra-sound: Its history and advances","authors":"J. Chauvel-Picard ,&nbsp;A.Gleizal ,&nbsp;H. Zahouani ,&nbsp;L. Tognetti ,&nbsp;E. Cinott ,&nbsp;E. Lange ,&nbsp;M. Suppa ,&nbsp;P. Rubegni ,&nbsp;V.Del Marmol ,&nbsp;C. Raffaelli ,&nbsp;P. Bahadoran ,&nbsp;J.-L. Perrot","doi":"10.1016/j.annder.2025.103437","DOIUrl":"10.1016/j.annder.2025.103437","url":null,"abstract":"<div><div>Skin ultrasound imaging has proven its complementarity with in vivo dermatoscopic and microscopic clinical dermatological examination in obtaining additional informations on the deep component of different skin pathologies. It is a reliable and non-invasive tool for evaluating the overall morphology of skin tumors or other pathologies such as Verneuil’s disease or other cystic pathologies.This article resumes the history of skin ultrasound imaging, its technical specificities and its practical uses. Optical imaging is not discussed, for which an article has already been devoted to it.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103437"},"PeriodicalIF":2.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical photography in dermatology: An ethical challenge 皮肤科临床摄影:伦理挑战。
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-01 DOI: 10.1016/j.annder.2025.103435
E. Demoulins , M. Moyal-Barracco , D. Penso-Assathiany , Groupe de Réflexion Éthique en Dermatologie GÉD of the French Society of Dermatology
{"title":"Clinical photography in dermatology: An ethical challenge","authors":"E. Demoulins ,&nbsp;M. Moyal-Barracco ,&nbsp;D. Penso-Assathiany ,&nbsp;Groupe de Réflexion Éthique en Dermatologie GÉD of the French Society of Dermatology","doi":"10.1016/j.annder.2025.103435","DOIUrl":"10.1016/j.annder.2025.103435","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103435"},"PeriodicalIF":2.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmune bullous dermatosis in children: French guidelines 儿童自身免疫性大疱性皮肤病:法国指南
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-12-01 DOI: 10.1016/j.annder.2025.103396
A. Welfringer-Morin , B. Tedbirt , H. Aubert , E. Abi-Nader , B. Pigneur , A.-C. Bursztejn , C. Droitcourt , L. Gusdorf , C. Le Roux-Villet , S. Mallet , S. Ingen-Housz-Oro , C. Prost-Squarcioni , C. Bodemer , P. Joly
{"title":"Autoimmune bullous dermatosis in children: French guidelines","authors":"A. Welfringer-Morin ,&nbsp;B. Tedbirt ,&nbsp;H. Aubert ,&nbsp;E. Abi-Nader ,&nbsp;B. Pigneur ,&nbsp;A.-C. Bursztejn ,&nbsp;C. Droitcourt ,&nbsp;L. Gusdorf ,&nbsp;C. Le Roux-Villet ,&nbsp;S. Mallet ,&nbsp;S. Ingen-Housz-Oro ,&nbsp;C. Prost-Squarcioni ,&nbsp;C. Bodemer ,&nbsp;P. Joly","doi":"10.1016/j.annder.2025.103396","DOIUrl":"10.1016/j.annder.2025.103396","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 4","pages":"Article 103396"},"PeriodicalIF":2.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145601680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Penile necrosis after intravesical instillation of mitomycin C 丝裂霉素C膀胱内灌注后阴茎坏死
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-11-26 DOI: 10.1016/j.annder.2025.103450
L. Galissi , V. Orlandini , P. Cirotteau , A. Pham-Ledard , M. Beylot-Barry
{"title":"Penile necrosis after intravesical instillation of mitomycin C","authors":"L. Galissi ,&nbsp;V. Orlandini ,&nbsp;P. Cirotteau ,&nbsp;A. Pham-Ledard ,&nbsp;M. Beylot-Barry","doi":"10.1016/j.annder.2025.103450","DOIUrl":"10.1016/j.annder.2025.103450","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103450"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145622337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicentric reticulohistiocytosis associated with metastatic melanoma: Therapeutic challenges 与转移性黑色素瘤相关的多中心网状组织细胞增生:治疗挑战
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-11-26 DOI: 10.1016/j.annder.2025.103448
N. Syyli , L. Tolkki , K. Suontama-Uusitalo , N. Kluger
{"title":"Multicentric reticulohistiocytosis associated with metastatic melanoma: Therapeutic challenges","authors":"N. Syyli ,&nbsp;L. Tolkki ,&nbsp;K. Suontama-Uusitalo ,&nbsp;N. Kluger","doi":"10.1016/j.annder.2025.103448","DOIUrl":"10.1016/j.annder.2025.103448","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103448"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145622339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxyurea-induced rosacea-like eruption in polycythemia vera 真性红细胞增多症中羟基脲诱导的酒渣鼻样爆发
IF 2.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2025-11-26 DOI: 10.1016/j.annder.2025.103449
X.-K. Xu, C.-R. Xiao, Y-Y Lin, H. Kang, L.-J. Su
{"title":"Hydroxyurea-induced rosacea-like eruption in polycythemia vera","authors":"X.-K. Xu,&nbsp;C.-R. Xiao,&nbsp;Y-Y Lin,&nbsp;H. Kang,&nbsp;L.-J. Su","doi":"10.1016/j.annder.2025.103449","DOIUrl":"10.1016/j.annder.2025.103449","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103449"},"PeriodicalIF":2.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145622340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annales De Dermatologie Et De Venereologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1